|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FMNL1 |
Gene summary for FMNL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FMNL1 | Gene ID | 752 |
| Gene name | formin like 1 | |
| Gene Alias | C17orf1 | |
| Cytomap | 17q21.31 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | O95466 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 752 | FMNL1 | male-WTA | Human | Thyroid | PTC | 5.43e-04 | 6.85e-02 | 0.1037 |
| 752 | FMNL1 | PTC05 | Human | Thyroid | PTC | 7.87e-03 | 2.41e-01 | 0.2065 |
| 752 | FMNL1 | PTC06 | Human | Thyroid | PTC | 1.12e-04 | 1.29e-01 | 0.2057 |
| 752 | FMNL1 | PTC07 | Human | Thyroid | PTC | 6.60e-09 | 1.37e-01 | 0.2044 |
| 752 | FMNL1 | ATC09 | Human | Thyroid | ATC | 1.19e-08 | 3.22e-01 | 0.2871 |
| 752 | FMNL1 | ATC11 | Human | Thyroid | ATC | 8.51e-03 | 3.22e-01 | 0.3386 |
| 752 | FMNL1 | ATC1 | Human | Thyroid | ATC | 4.18e-09 | 3.60e-01 | 0.2878 |
| 752 | FMNL1 | ATC2 | Human | Thyroid | ATC | 4.99e-14 | 1.10e+00 | 0.34 |
| 752 | FMNL1 | ATC3 | Human | Thyroid | ATC | 1.54e-04 | 3.39e-01 | 0.338 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022604112 | Thyroid | PTC | regulation of cell morphogenesis | 165/5968 | 309/18723 | 2.60e-15 | 1.82e-13 | 165 |
| GO:0008360111 | Thyroid | PTC | regulation of cell shape | 86/5968 | 154/18723 | 6.22e-10 | 1.95e-08 | 86 |
| GO:0030865110 | Thyroid | PTC | cortical cytoskeleton organization | 38/5968 | 61/18723 | 9.77e-07 | 1.46e-05 | 38 |
| GO:003086616 | Thyroid | PTC | cortical actin cytoskeleton organization | 25/5968 | 40/18723 | 6.51e-05 | 5.72e-04 | 25 |
| GO:00510144 | Thyroid | PTC | actin filament severing | 10/5968 | 16/18723 | 1.13e-02 | 4.49e-02 | 10 |
| GO:002260429 | Thyroid | ATC | regulation of cell morphogenesis | 171/6293 | 309/18723 | 2.36e-15 | 1.70e-13 | 171 |
| GO:000836026 | Thyroid | ATC | regulation of cell shape | 91/6293 | 154/18723 | 7.33e-11 | 2.31e-09 | 91 |
| GO:003086523 | Thyroid | ATC | cortical cytoskeleton organization | 41/6293 | 61/18723 | 8.28e-08 | 1.43e-06 | 41 |
| GO:003086617 | Thyroid | ATC | cortical actin cytoskeleton organization | 28/6293 | 40/18723 | 2.77e-06 | 3.19e-05 | 28 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FMNL1 | SNV | Missense_Mutation | c.1378N>A | p.Pro460Thr | p.P460T | O95466 | protein_coding | tolerated(0.58) | benign(0.007) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FMNL1 | SNV | Missense_Mutation | c.3289G>A | p.Glu1097Lys | p.E1097K | O95466 | protein_coding | deleterious_low_confidence(0.02) | benign(0.404) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| FMNL1 | SNV | Missense_Mutation | c.850N>A | p.Gly284Arg | p.G284R | O95466 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| FMNL1 | SNV | Missense_Mutation | c.635N>A | p.Arg212Lys | p.R212K | O95466 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FMNL1 | SNV | Missense_Mutation | rs146945062 | c.941N>A | p.Arg314Gln | p.R314Q | O95466 | protein_coding | tolerated(0.09) | benign(0) | TCGA-C5-A7CG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| FMNL1 | SNV | Missense_Mutation | rs778995612 | c.2974N>T | p.Arg992Cys | p.R992C | O95466 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| FMNL1 | SNV | Missense_Mutation | c.768N>C | p.Glu256Asp | p.E256D | O95466 | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FMNL1 | SNV | Missense_Mutation | c.839N>C | p.Cys280Ser | p.C280S | O95466 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FMNL1 | SNV | Missense_Mutation | c.2779N>C | p.Glu927Gln | p.E927Q | O95466 | protein_coding | deleterious(0) | possibly_damaging(0.898) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FMNL1 | SNV | Missense_Mutation | novel | c.1421N>T | p.Ser474Leu | p.S474L | O95466 | protein_coding | tolerated(0.09) | benign(0.368) | TCGA-MA-AA3X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |